Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Ascending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00173-0713-25 00173-0713 Busulfan Myleran Chemotherapy Alkylating Agent Alkylsulfonate Oral March 21, 1985 March 31, 2014 No Longer Used
76388-0713-25 76388-0713 Busulfan Myleran 2.0 mg/1 Chemotherapy Alkylating Agent Alkylsulfonate Oral March 21, 1985 June 30, 2023 No Longer Used
00008-4510-01 00008-4510 Gemtuzumab ozogamicin Mylotarg 5.0 mg/5mL Immunotherapy Drug Antibody Conjugate CD33 Intravenous Sept. 7, 2017 In Use
54868-6366-00 54868-6366 Isotretinoin Myorisan 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 23, 2012 In Use
54868-6378-00 54868-6378 Isotretinoin Myorisan 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Oct. 29, 2012 In Use
61748-0301-01 61748-0301 Isotretinoin Myorisan 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0301-11 61748-0301 Isotretinoin Myorisan 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0301-13 61748-0301 Isotretinoin Myorisan 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0302-01 61748-0302 Isotretinoin Myorisan 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0302-11 61748-0302 Isotretinoin Myorisan 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0302-13 61748-0302 Isotretinoin Myorisan 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0303-01 61748-0303 Isotretinoin Myorisan 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 26, 2015 In Use
61748-0303-11 61748-0303 Isotretinoin Myorisan 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 26, 2015 In Use
61748-0303-13 61748-0303 Isotretinoin Myorisan 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 26, 2015 In Use
61748-0304-01 61748-0304 Isotretinoin Myorisan 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0304-11 61748-0304 Isotretinoin Myorisan 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0304-13 61748-0304 Isotretinoin Myorisan 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
80978-0111-06 80978-0111 Nelarabine injection NELARABINE 250.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous April 12, 2023 In Use
46708-0813-50 46708-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
46708-0813-63 46708-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
62332-0813-50 62332-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
62332-0813-63 62332-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
00069-0324-01 00069-0324 Pegfilgrastim-apgf NYVEPRIA 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Dec. 15, 2020 In Use
64370-0532-01 64370-0532 Vinorelbine tartrate Navelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Nov. 15, 2005 Oct. 31, 2021 No Longer Used
64370-0532-02 64370-0532 Vinorelbine tartrate Navelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Nov. 15, 2005 Oct. 31, 2021 No Longer Used

Found 10,000 results in 10 milliseconds — Export these results